Ogeda
47 Rue Adrienne Bolland
Gosselies
6041
Tel: 32-71-348- 500
Website: https://www.ogeda.com
Email: info@ogeda.com
About Ogeda
Ogeda is a Belgium-based, privately owned clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting GPCRs. Ogeda’s orally-available and proprietary lead drug candidate fezolinetant (ESN364) is currently in Phase II clinical development for the treatment of women’s health disorders. Ogeda has additional small molecules targeting GPCRs in preclinical development in multiple therapeutic areas including inflammatory and autoimmune diseases. Ogeda is backed by leading investors, including Vesalius Biocapital, Fund+ and SRIW.4 articles about Ogeda
-
Tokyo-based Astellas Pharma announced that its roxadustat met its primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease (CKD) patients with anemia not on dialysis. The focus of the drug is on anemia.
-
Astellas Completes Acquisition Of Ogeda
5/17/2017
-
Ogeda Announces Positive Data From Phase IIa Trial Of Fezolinetant (ESN364) In The Treatment Of Menopausal Hot Flashes
1/4/2017
-
Ogeda Announces Fezolinetant As INN And Issuance Of U.S. Patent For ESN364
12/20/2016